{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:28:48Z","timestamp":1792546128511,"version":"4.5.0"},"reference-count":34,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.271129","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:17:59Z","timestamp":1785269879000},"page":"910-920","source":"Crossref","is-referenced-by-count":2,"title":["Fibroblast Activation ProteinTargeted Radiopharmaceutical Therapy Using\n                    <sup>177<\/sup>\n                    Lu-,\n                    <sup>90<\/sup>\n                    Y-, and\n                    <sup>225<\/sup>\n                    Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies"],"prefix":"10.2967","volume":"67","author":[{"given":"Richard P.","family":"Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Greifenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Eismant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Ghai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Klega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Landvogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Benz-Zils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortwin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Jaeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026060105301020000_67.6.910.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889"},{"key":"2026060105301020000_67.6.910.2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.rcl.2021.05.006","article-title":"PET imaging of neuroendocrine tumors","volume":"59","author":"Galgano","year":"2021","journal-title":"Radiol Clin North Am."},{"key":"2026060105301020000_67.6.910.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263274"},{"key":"2026060105301020000_67.6.910.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.004"},{"key":"2026060105301020000_67.6.910.5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/pharmaceutics14061284","article-title":"Combination of [177Lu]Lu-DOTA-TATE targeted radionuclide therapy and photothermal therapy as a promising approach for cancer treatment: in vivo studies in a human xenograft mouse model","volume":"14","author":"Simon","year":"2022","journal-title":"Pharmaceutics."},{"key":"2026060105301020000_67.6.910.6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/cancers7040902","article-title":"Cancer-associated fibroblasts: their characteristics and their roles in tumor growth","volume":"7","author":"Shiga","year":"2015","journal-title":"Cancers (Basel)."},{"key":"2026060105301020000_67.6.910.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2011.09.001"},{"key":"2026060105301020000_67.6.910.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210435"},{"key":"2026060105301020000_67.6.910.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2026060105301020000_67.6.910.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"2026060105301020000_67.6.910.11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0225"},{"key":"2026060105301020000_67.6.910.12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0647"},{"key":"2026060105301020000_67.6.910.13","doi-asserted-by":"publisher","DOI":"10.1159\/000069863"},{"key":"2026060105301020000_67.6.910.14","first-page":"1639","article-title":"A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2026060105301020000_67.6.910.15","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","author":"Millul","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301020000_67.6.910.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262533"},{"key":"2026060105301020000_67.6.910.17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics."},{"key":"2026060105301020000_67.6.910.18","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026060105301020000_67.6.910.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267281"},{"key":"2026060105301020000_67.6.910.20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiol.212430","article-title":"68Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET\/CT","volume":"304","author":"Fu","year":"2022","journal-title":"Radiology."},{"key":"2026060105301020000_67.6.910.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264544"},{"key":"2026060105301020000_67.6.910.22","first-page":"S2271","article-title":"177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: initial data from a phase 1\/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)","volume":"63","author":"McConathy","year":"2022","journal-title":"J Nucl Med."},{"key":"2026060105301020000_67.6.910.23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[177Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301020000_67.6.910.24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301020000_67.6.910.25","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00259-024-06635-8","article-title":"[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET\/CT imaging in patients with various type of metastatic cancers","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301020000_67.6.910.26","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1007\/s00259-024-06626-9","article-title":"Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET\/CT in various cancer patients","volume":"51","author":"Liu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026060105301020000_67.6.910.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05842-5"},{"key":"2026060105301020000_67.6.910.28","doi-asserted-by":"crossref","unstructured":"Zboralski D, Osterkamp F, von Hacht JL, et al. Preclinical development of 3BP-3940, a fibroblast activation protein-targeted cyclic peptide-based radiotheranostic for imaging and therapy. J Nucl Med. 2026;67:594600.","DOI":"10.2967\/jnumed.125.271452"},{"key":"2026060105301020000_67.6.910.29","doi-asserted-by":"crossref","first-page":"108541","DOI":"10.1016\/j.isci.2023.108541","article-title":"3BP-3940, a highly potent FAP-targeting peptide for theranostics: production, validation and first in human experience with Ga-68 and Lu-177","volume":"26","author":"Greifenstein","year":"2023","journal-title":"iScience."},{"key":"2026060105301020000_67.6.910.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239"},{"key":"2026060105301020000_67.6.910.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04612-0"},{"key":"2026060105301020000_67.6.910.32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-term nephrotoxicity after PRRT: myth or reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics."},{"key":"2026060105301020000_67.6.910.33","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56211"},{"key":"2026060105301020000_67.6.910.34","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/diagnostics12081926","article-title":"Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225Ac- and 177Lu-labeled PSMA ligands (tandem-PRLT) in advanced prostate cancer: a single-center systematic investigation","volume":"12","author":"Langbein","year":"2022","journal-title":"Diagnostics (Basel)."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:32Z","timestamp":1785269912000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.271129"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271129","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}